Patents by Inventor Doris Damian
Doris Damian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240133865Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: ApplicationFiled: May 24, 2023Publication date: April 25, 2024Applicant: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo, Jeffrey R. Luber
-
Publication number: 20240019417Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: ApplicationFiled: May 5, 2023Publication date: January 18, 2024Applicant: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Publication number: 20230293461Abstract: Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.Type: ApplicationFiled: March 23, 2023Publication date: September 21, 2023Applicant: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Patent number: 11674948Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: GrantFiled: August 6, 2018Date of Patent: June 13, 2023Assignee: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo, Jeffrey R. Luber
-
Publication number: 20200188335Abstract: Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.Type: ApplicationFiled: December 13, 2019Publication date: June 18, 2020Applicant: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Patent number: 10525020Abstract: Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.Type: GrantFiled: February 9, 2016Date of Patent: January 7, 2020Assignee: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Publication number: 20180348199Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: ApplicationFiled: August 6, 2018Publication date: December 6, 2018Applicant: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo, Jeffrey R. Luber
-
Patent number: 10041932Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: GrantFiled: September 25, 2015Date of Patent: August 7, 2018Assignee: Laboratory Corporation of America HoldingsInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo, Jeffrey R. Luber
-
Publication number: 20160231311Abstract: Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.Type: ApplicationFiled: February 9, 2016Publication date: August 11, 2016Inventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Publication number: 20160091481Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: ApplicationFiled: September 29, 2015Publication date: March 31, 2016Inventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Publication number: 20160091480Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: ApplicationFiled: September 25, 2015Publication date: March 31, 2016Inventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo, Jeffrey R. Luber
-
Patent number: 9176113Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: GrantFiled: February 27, 2015Date of Patent: November 3, 2015Assignee: SynapDx CorporationInventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Publication number: 20150293072Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: ApplicationFiled: February 27, 2015Publication date: October 15, 2015Inventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
-
Publication number: 20150294081Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.Type: ApplicationFiled: September 22, 2014Publication date: October 15, 2015Inventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo, Jeffrey R. Luber, Stanley N. Lapidus
-
Patent number: 8321154Abstract: Markers are provided for detecting coronary artery disease. Levels of these markers are indicative of a patient being at risk of having or developing coronary artery disease.Type: GrantFiled: March 24, 2008Date of Patent: November 27, 2012Assignee: BG Medicine, Inc.Inventors: Aram S. Adourian, Doris Damian, Amir Handzel
-
Patent number: 8206986Abstract: Markers are provided that are predictive of Alzheimer's disease. Levels of these markers, when different from a standard, are indicative of a patient being at risk of having or developing Alzheimer's disease.Type: GrantFiled: March 13, 2006Date of Patent: June 26, 2012Assignee: BG Medicine, Inc.Inventors: Doris Damian, Amir Handzel, Aram Adourian
-
Publication number: 20110010099Abstract: The present teachings relate to gaining insight into biological states, e.g., disease states or drugged states, by gathering, integrating, and combining biomolecular data. More particularly, the present teachings relate to methods and systems for profiling a state of a biological system, finding accessible biomarkers representative of the state of a biological system, and deriving insights into the biochemistry of a biological system for therapeutic, diagnostic, prognostic and other purposes.Type: ApplicationFiled: September 19, 2006Publication date: January 13, 2011Inventors: Aram S Adourian, Matej Oresic, Doris Damian, Eric K. Neumann, Thomas Plasterer, Ezra Jennings
-
Publication number: 20100273661Abstract: A method for predicting treatment response of a type II diabetes patient to rosiglitazone is provided. The method involves at least one sample from a patient having type II diabetes and analyzing biomarkers predictive of a patient who will respond to treatment with rosiglitazone. The biomarkers include, at least, interleukin-8, histidine, citrate. These biomarkers are identified in at least one classification analyses selected from the group consisting of a majority-vote based classifier and support-vector machine (SVM) classifier. Also provided is a method for predicting treatment response of a type II diabetes patient to glyburide at 8 weeks post-initiation of therapy. The method involves obtaining a sample from a type II diabetes patient who has been treated with glyburide for about 4 weeks and analyzing biomarkers predictive of a patient who will respond to treatment with glyburide at 8 weeks. The biomarkers useful in this method include, at least, sphingomyelin 23:1 and L-phenylalanine.Type: ApplicationFiled: June 11, 2008Publication date: October 28, 2010Applicants: SmithKline Beecham Corporation, BG Medicine IncInventors: Yang Qiu, Dilip Rajagopalan, Lei Zhu, Susan C Connor, Guanghui Hu, David Maclean, Doris Damian, Amir Handzel, Rajalakshmi Balasubramanian
-
Publication number: 20100173346Abstract: Markers are provided for detecting coronary artery disease. Levels of these markers are indicative of a patient being at risk of having or developing coronary artery disease.Type: ApplicationFiled: March 24, 2008Publication date: July 8, 2010Applicant: BG MEDICINE, INC.Inventors: Aram Adourian, Doris Damian, Amir Handzel
-
Publication number: 20090211346Abstract: Markers are provided that are predictive of Alzheimer's disease. Levels of these markers, when different from a standard, are indicative of a patient being at risk of having or developing Alzheimer's disease.Type: ApplicationFiled: March 13, 2006Publication date: August 27, 2009Inventors: Doris Damian, Amir Handzel, Aram Adourian